Retension Pharmaceuticals
RTSN12.2700.16% ( +0.020 )
Valuation
Current ValuationThe current P/E ratio is -7.18, within the reasonable range, cheaper than 56% of the time in the past 1 years, and the industry ranks 181/257, the industry Median -0.95.
-7.18xP/E
$12.27Stock price
$-1.71Earnings per share
-7.18xP/E
Stock price$12.27Earnings per share$-1.71
Historical Valuation
P/E ratioTypical rangeMedian
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
03876114152
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.